Bellerophon Therapeutics, Inc. (BLPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
BLPH Stock Price Chart Interactive Chart >
BLPH Price/Volume Stats
| Current price | $2.10 | 52-week high | $3.50 |
| Prev. close | $2.10 | 52-week low | $0.67 |
| Day low | $2.06 | Volume | 35,870 |
| Day high | $2.16 | Avg. volume | 3,629,667 |
| 50-day MA | $1.40 | Dividend yield | N/A |
| 200-day MA | $1.27 | Market Cap | 20.04M |
Bellerophon Therapeutics, Inc. (BLPH) Company Bio
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Bellerophon Therapeutics, Inc. was founded in 2009 and is founded in Warren, New Jersey.
Latest BLPH News From Around the Web
Below are the latest news stories about BELLEROPHON THERAPEUTICS INC that investors may wish to consider to help them evaluate BLPH as an investment opportunity.
Bellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung DiseaseEnrollment concludes earlier than anticipated; pivotal top-line data now expected mid-2023WARREN, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient has been enrolled in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to start off the day with a breakdown of the biggest pre-market stock movers making the news on Wednesday morning! |
Companies Like Bellerophon Therapeutics (NASDAQ:BLPH) Could Be Quite RiskyJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Bellerophon Therapeutics Shares Gained Over 200% TodayBellerophon Therapeutics Inc (NASDAQ: BLPH) entered into a license agreement for the development and commercialization of INOpulse with Baylor BioSciences. Under the terms of the license agreement, Bellerophon will receive a license payment of $6 million. Additionally, Bellerophon is entitled to royalties of 5% on net sales resulting from all licensed INOpulse indications within Greater China. Baylor BioSciences will receive exclusive rights to develop and commercialize INOpulse within Greater C |
Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse® in Greater China with Baylor BioSciencesBellerophon to receive a license payment of $6 million, as well as royalties on net sales in Greater ChinaWARREN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered into a license agreement for the development and commercialization of INOpulse® with Baylor BioSciences, a life sciences compa |
BLPH Price Returns
| 1-mo | 149.41% |
| 3-mo | 96.26% |
| 6-mo | 39.07% |
| 1-year | -3.67% |
| 3-year | -60.78% |
| 5-year | -94.19% |
| YTD | 133.33% |
| 2022 | -70.97% |
| 2021 | -53.52% |
| 2020 | 27.16% |
| 2019 | -56.29% |
| 2018 | -68.99% |
Loading social stream, please wait...